Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database |
| Type de publication | Journal Article |
| Year of Publication | 2021 |
| Auteurs | Casarotto E, Chandwani S, Mortier L, Dereure O, Dutriaux C, Dalac S, Scherrer E, Levy-Bachelot L, Verdoni L, Farge G, Allayous C, Oriano B, Dalle S, Lebbe C |
| Journal | IMMUNOTHERAPY |
| Volume | 13 |
| Pagination | 905-916 |
| Date Published | AUG |
| Type of Article | Article |
| ISSN | 1750-743X |
| Mots-clés | cohort study, Immunotherapy, Melanoma, oncology, Pembrolizumab, survival |
| Résumé | Aim: To describe real-world pembrolizumab administration and outcomes for advanced melanoma in France. Materials & methods: Using the MelBase longitudinal database, this multicenter historical-prospective study examined treatment and outcomes of patients with nonuveal, unresectable stage III/IV melanoma initiating pembrolizumab from April 2016 to September 2017, with follow-up to September 2019. Kaplan-Meier time-to-event analyses were conducted. Results: Of 223 patients (median age 67; 51% men), 134 (60%), 36 (16%) and 53 (24%) initiated pembrolizumab in first-, second- and third-line, respectively. Median overall survival (months) was 32.6 (95% CI: 20.3-not reached [NR]), 14.4 (8.6-NR) and 9.3 (6.4-NR), respectively. Best real-world tumor response of complete or partial response was recorded for 49, 39 and 26% of patients, respectively. Conclusion: Study results support benefits of pembrolizumab therapy for advanced melanoma. |
| DOI | 10.2217/imt-2021-0077 |